Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
JNJ Stock Chart & Stats
$240.40
-$4.08(-2.79%)
At close: 4:00 PM EST
$240.40
-$4.08(-2.79%)
Day’s Range― - ―
52-Week Range$141.50 - $251.71
Previous CloseN/A
Volume3.80M
Average Volume (3M)8.78M
Market Cap
$579.34B
Enterprise Value$607.56B
Total Cash (Recent Filing)$20.10B
Total Debt (Recent Filing)$47.93B
Price to Earnings (P/E)18.8
Beta0.11
Next Earnings
Apr 14, 2026EPS Estimate
2.69Next Dividend Ex-DateN/A
Dividend Yield2.5%
Share Statistics
EPS (TTM)2.46
Shares Outstanding2,409,899,000
10 Day Avg. Volume9,209,865
30 Day Avg. Volume8,777,029
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue6.45
Enterprise Value/Gross Profit8.86
Enterprise Value/Ebitda15.25
Forecast
1Y Price Target
$245.14Price Target Upside1.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)11.57
Revenue Forecast (FY)$100.52B
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessRobust MajesTEC results for Tecvayli reinforce its role in multiple myeloma treatment and strengthen expected demand for combination regimens involving Darzalex.
New Product Launches And UptakeAnticipated launches and growing uptake of medicines such as Inlexzo and Tremfya provide a clear path to revenue growth that can help offset losses from aging products.
Portfolio Strategy And Patent RunwayA diversified mix across pharmaceuticals and medical devices, combined with a long patent runway and strategic portfolio moves like the orthopaedics separation, supports a premium valuation and margin improvement potential.
Bears Say
Competitive And Pipeline UncertaintyNew generic entrants and declines in older blockbusters, together with a sparse set of near-term high-impact pipeline catalysts, could weigh on revenue momentum and limit re-rating potential.
Litigation RiskOngoing talc litigation and other legal exposures remain unresolved risks that could generate material costs and constrain share performance.
Valuation LimitationCurrent premium valuation reduces the likelihood of significant upside from multiple expansion, leaving returns dependent on execution and product momentum.
Johnson & Johnson News
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $141.50 and its highest was $251.71 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $579.34B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Apr 14, 2026 which is in 36 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jan 21, 2026. The company reported $2.46 earnings per share for the quarter, missing the consensus estimate of $2.463 by -$0.003.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 2.5%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.69.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,899,000 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.46 in its last earnings report, missing expectations of $2.463. Following the earnings report the stock price went down -0.092%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in JNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$245.14 (1.97% Upside)
$245.14 (1.97% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 90%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $79.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 95%
Bearish news 5%
Bearish news 5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.00%
12-Months-Change
Fundamentals
Return on Equity
35.03%
Trailing 12-Months
Asset Growth
10.61%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
JNJ Company Deck
JNJ Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights a dominant message of accelerating, portfolio-driven growth: robust revenue and adjusted EPS growth, strong free cash flow, numerous approvals and late-stage programs, and notable commercial momentum across oncology, immunology, neuroscience, and MedTech. Management provided constructive 2026 guidance, reiterated long-term ambition (double-digit growth by the end of the decade), and outlined capital deployment and the orthopedics separation. Offsetting risks include material STELARA biosimilar erosion (a substantial multi-hundred-basis-point headwind), elevated litigation and one-time charges, tariff pressures, competitive dynamics in select MedTech areas, and modest share-count dilution. On balance, the positives — broad-based commercial strength, pipeline and approval milestones, robust cash generation, and clear guidance — materially outweigh the near-term headwinds.View all JNJ earnings summariesJNJ Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
$245.14
▲(1.97% Upside)
Technical Analysis
Ownership Overview
0.03% Insiders
18.19% Mutual Funds
6.42% Other Institutional Investors
52.79% Public Companies and Individual Investors